Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyDamas: Amivantamab and Cetrelimab in Metastatic NSCLC
NCT05908734Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of amivantamab, cetrelimab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started May 2023; status: active, not recruiting.
02
Drugs
amivantamabcetrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05908734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908734.